Current management of tuberculosis.
Current chemotherapeutic regimens against tuberculosis give excellent cure rates and low relapse rates if implemented and monitored correctly. This is fortunate since only two new drugs have been approved for use in this condition in the last 30 years. However, shortcomings in management and in patient compliance have resulted in an increasing prevalence of drug-resistant organisms. The global decline in the disease has been reversed due to a combination of factors including the HIV epidemic, ageing populations, poverty, and translocation of refugee populations due to conflict.
Bayer Pharma, Stoke Court, Stoke Poges, Slough, SL2 4LY, UK.
N J
NJ
Snell
D000818:Animals; D000995:Antitubercular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D009169:Mycobacterium tuberculosis; D014397:Tuberculosis, Pulmonary / Q000276:immunology / Q000473:pathology / Q000628:therapy*
D000995:Antitubercular Agents